Search Results for “EC” – Page 287 – media

Inclusion of noncommunicable disease care in response to humanitarian emergencies will help save more lives

Noncommunicable diseases (NCDs), such as cardiovascular disease, cancer, chronic respiratory disease and diabetes, are responsible for 75% of deaths worldwide. People affected by humanitarian emergencies are at increased risk of NCDs. It is estimated that strokes and heart attacks are up to 3 times more likely following a disaster. However, care and treatment for NCDs are often not included as a standard part of humanitarian emergency preparedness and response, which focus on the most immediate needs. To support integration of essential services for NCDs into emergency preparedness and humanitarian response, the World Health Organization (WHO), the Kingdom of Denmark, the Hashemite Kingdom of Jordan, the Republic of Kenya, and UNHCR, the UN Refugee Agency, are jointly convening a global high-level technical meeting on NCDs in humanitarian settings on 27-29 February in Copenhagen, Denmark. Humanitarian emergencies in recent years are becoming more complex and interconnected. Hunger and shortages of essential goods ...
- Source: drugdu
- 118
- February 29, 2024
China Pharma Holdings Inc. Announces 1-for-5 Reverse Stock Split

HAIKOU, China, Feb. 24, 2024 /PRNewswire/ — China Pharma Holdings Inc. (“China Pharma” or the “Company”) (NYSE American: CPHI) reported that it expects to implement a 1-for-5 reverse stock split on its common stock effective Wednesday, March 6, 2024, with trading to begin on a split-adjusted basis at the market open on that day. Trading in the common stock will continue on the NYSE American under the symbol “CPHI”. The new CUSIP number for the common stock following the reverse stock split is 16941T-302. The reverse stock split at a ratio of 1-for-5 shares was approved by the Company’s Board of Directors through unanimous written consent on October 16, 2023 and adopted by the Company’s stockholders through Annual Meeting for the fiscal year ended on December 31, 2022, which was held on December 17, 2023. Upon the effectiveness of the reverse stock split, every 5 shares of the Company’s issued ...
- Source: drugdu
- 90
- February 29, 2024
Hengrui Pharmaceuticals’ PD-L1 Inhibitor Adebelizumab Combined with HER2 ADC SHR-A1811 Approved for Breast Cancer Clinical Treatment

Recently, Hengrui Pharmaceuticals’ subsidiaries, Shanghai Shengdi Pharmaceuticals Co., Ltd. and Suzhou Shengdia Biopharmaceuticals Co., Ltd. received the Notice of Approval for Drug Clinical Trial approved by the State Drug Administration, which authorizes the company to carry out the clinical trial of adelberizumab in combination with SHR-A1811 for the treatment of breast cancer. According to the data released by the International Agency for Research on Cancer (IARC) of the World Health Organization in 2020, breast cancer has become the world’s number one malignant tumor and is the most common malignant tumor in women. Statistics show that in 2020, there were about 2.26 million newly diagnosed cases of female breast cancer and 685,000 deaths worldwide, ranking first in female malignant tumor morbidity and mortality. The incidence and mortality rates of breast cancer worldwide vary according to regional distribution. In China, the 2020 China Cancer data show that the incidence rate of breast ...
- Source: drugdu
- 127
- February 29, 2024
Sponge-on-a-string test to benefit NHS patients with oesophageal cancer

Eight out of ten patients who took the test were discharged without needing further testing The NHS has announced that a simple sponge-on-a-string test developed by researchers from the early cancer institute at the University of Cambridge will replace the need for endoscopy to prevent oesophageal cancer. The NHS trialled the test to help diagnose Barrett’s oesophagus, a condition that affects the food pipe and can lead to oesophageal cancer. Responsible for around 9,200 new cases every year in the UK, oesophageal cancer occurs in the long, hollow tube that runs from the throat to the stomach, known as the oesophagus. During the pandemic, the NHS began piloting the test at 30 hospitals across 17 areas in England, including Manchester, Plymouth, London, Kent and Cumbria. The test requires the patient to swallow a small capsule-shaped device containing a small sponge that collects cell samples for analysis before being extracted via ...
- Source: drugdu
- 135
- February 29, 2024
UK and Netherlands researchers call for funding to investigate cancer treatments

The white paper outlines three strategic recommendations to support further research Researchers from King’s College London and Erasmus MC in the Netherlands have called for further funding support in a recently published white paper to investigate the use of radioactive cancer-targeted drugs to improve cancer treatments. The white paper, Unlocking the Full Potential of Cancer Treatments Using Targeted Radionuclide Therapy through Netherlands-UK Partnerships, outlined three strategic recommendations to achieve this. Most radioactive drugs are used to specifically deliver a radiation dose to cancer cells to produce a therapeutic effect. They are used to treat the disease areas identified on medical scans but can also specifically target the microscopic tumour deposits, which are involved in the progression of the disease. More specifically, targeted radionuclide therapy, a type of radiation therapy, is effective to treat prostate cancer and some other types of cancer where radionuclide, a radioactive chemical, is linked to cell-targeting ...
- Source: drugdu
- 152
- February 29, 2024
Alzheimer’s Blood Test Could Soon Replace Invasive Spinal Taps and Brain Scans

Historically, Alzheimer’s disease was primarily diagnosed based on observable symptoms, particularly when individuals started exhibiting memory and cognitive difficulties. However, it’s been revealed through research that up to a third of individuals diagnosed with Alzheimer’s based solely on cognitive symptoms have been incorrectly diagnosed, with their symptoms stemming from other causes. The accurate identification of Alzheimer’s disease has become increasingly crucial, especially since the introduction of the first treatments that can slow the disease’s progression, along with other promising drugs currently in development. These treatments are potentially more effective when administered early, highlighting the need for early detection of the disease. Therefore, to qualify for Alzheimer’s therapies, patients must show cognitive impairment and test positive for amyloid plaques, which are distinctive to Alzheimer’s. Techniques like amyloid positron emission tomography (PET) brain scans, cerebrospinal fluid analyses, and blood tests are used to detect brain amyloid plaques. However, these are only employed ...
- Source: drugdu
- 156
- February 28, 2024
Teva, Jiangsu Nhwa Ink Strategic Partnership Deal Focused on Patient Access to Austedo in China

Don Tracy, Associate Editor Collaboration aims to leverage Nhwa’s expertise in the country’s neuro-psychiatric health sector. Today, Teva announced that it has entered into a collaboration with Nhwa Pharmaceutical Co., Ltd with the goal of providing easier access to Teva’s drug Austedo in China. Austedo focuses on the treatment of neurodegenerative and movement disorders, particularly chorea associated with Huntington disease (HD) and tardive dyskinesia (TD) in adults. According to Teva, the partnership is a part of its goal of expanding the medication as a global brand, as it earned approximately over $1.2 billion in profits last year. Further, Teva reported that Austedo is the first deuterated drug to be approved in China. Deuteration involves replacing hydrogen atoms with deuterium, which can slow down the drug’s metabolism, allowing for less frequent dosing and potentially improving patient compliance.1 “We are committed to addressing the pressing needs of patients in China with more ...
- Source: drugdu
- 117
- February 28, 2024
Asthma Medication Xolair May Reduce Peanut Allergies, New Study Finds

Mike Hollan FDA has approved the medication in adults and children with allergies. A peanut allergy can be a difficult and terrifying thing to live with. People with these allergies have to be on constant alert, as coming into contact with even a small amount of the food can cause a severe reaction. Thousands of Americans live with these allergies, and they are responsible for a similar number of emergency room visits. Typically, the best way to treat a peanut is to just avoid them altogether, which can be difficult due to how common nuts and nut oils are used in cooking. A recent announcement from Novartis, however, may make life a lot easier (and much less scary) for people living with these allergies. Novartis released that data from a new study which suggests that asthma medication Xolair can be used to treat certain food allergies, including nuts, eggs, milk, ...
- Source: drugdu
- 89
- February 28, 2024
Qyuns Therapeutics passed the IPO hearing on the Main Board of the Hong Kong Stock Exchange

According to the Hong Kong Stock Exchange, on February 26, Jiangsu Qyuns Therapeutics-B passed the IPO hearing on the main board of the Hong Kong Stock Exchange and will be listed soon. It is reported that Qyuns Therapeutics was established in 2015. It is a clinical-stage biotechnology company completely focused on biotherapeutics of autoimmune and allergic diseases, covering four major disease areas: skin, rheumatism, respiratory and digestive tract diseases. According to its official website, based on its complete independent innovation capabilities, Qyuns Therapeutics has formed two core products, QX002N and QX005N, as well as a product pipeline of seven other drug candidates. One variety has been accepted by BLA, one is in clinical phase 3, and four varieties are in clinical phase 2 and 1 respectively. The indications cover silver eyebrow disease, atopic dermatitis, ankylosing spondylitis, systemic lupus erythematosus, It covers four major disease areas including asthma, inflammatory bowel disease, ...
- Source: drugdu
- 95
- February 28, 2024
TransThera initiates IND-Enabling studies for TT-02332, a novel, highly potent and CNS-penetrating NLRP3 inhibitor

NANJING, China and GAITHURSBURG, Md., Feb. 26, 2024 /PRNewswire/ — TransThera, a clinical-stage biopharmaceutical company dedicated to innovating differentiated drugs globally, today announced the initiation of IND-enabling studies for TT-02332, a potent, selective and highly CNS-penetrating NLRP3 inflammasome inhibitor. The NLRP3 inflammasome is a pivotal component of the human innate immune system. Aberrant activation of NLRP3 is strongly linked with a variety of inflammatory disorders, including obesity, neurodegenerative diseases, NASH, inflammatory bowel disease (IBD), dermatitis, and atherosclerosis. “Immuno-inflammation is one of TransThera’s key therapeutic areas of interest. Over the past three years, we have achieved breakthroughs with the NLRP3 inhibitor program.” said Jennifer Sheng, Vice President of Biology at TransThera. “Our clinical candidate compound TT-02332 is a highly potent NLRP3 inhibitor that has shown promising efficacy in a number of disease-relevant in vivo animal models. The compound exhibits desirable pharmacokinetic/ pharmacodynamic (PK/PD) properties, suitable for once-daily dosing. TT-02332 demonstrates an ...
- Source: drugdu
- 134
- February 28, 2024

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.